Trial Profile

Clinical study of TJM2, to fight "cytokine storm" during severe COVID-19 disease.

Status: Planning

Phase of Trial: Phase I

Latest Information Update: 26 Nov 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Plonmarlimab (Primary)
Indications Cytokine release syndrome
Focus Therapeutic Use
Sponsors NovaBridge Biosciences

Most Recent Events

29 Oct 2025 According to NovaBridge Biosciences media release, I-MAB Biopharma has changed its name to NovaBridge Biosciences.
30 Mar 2020 According to I-Mab Biopharma media release, it has submitted an Investigational New Drug (IND) application to South Korea's Ministry of Food and Drug Safety
30 Mar 2020 According to I-Mab Biopharma media release, The results from the planned COVID-19 CS study will also be used to further evaluate the potential therapeutic role of TJM2 in reducing or preventing CS and neurotoxicity associated with CAR-T therapy

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com